Latest On Celyad Oncology SA (CYAD):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-05 10:02 EST | News | Celyad plans to delist from Nasdaq amid cash woes | N/A |  |
| 2023-04-25 02:08 EST | News | Celyad Oncology receives non-compliance letter from Nasdaq | N/A | |
| 2023-04-05 02:22 EST | News | Celyad Oncology receives Nasdaq non-compliance notice | N/A | |
| 2023-03-24 21:56 EST | News | Celyad Oncology SA (CYAD) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-24 05:51 EST | News | Celyad Oncology GAAP EPS of -€1.81 | N/A | |
| 2023-03-24 05:51 EST | News | Celyad Oncology appoints former exec as CEO | N/A | |
| 2023-03-15 07:00 EST | News | Celyad slumps ~30% as board to put proposal to continue activities on vote at shareholders' meet | N/A | |
| 2023-02-03 04:07 EST | News | Celyad Oncology gives Q4 update and 2023 outlook | N/A | |
| 2022-12-21 16:50 EST | News | Celyad stock slumps 25% as blood cancer drug CYAD-211 gets axed in strategic review | N/A | |
| 2022-09-20 11:12 EST | News | Celyad to sell cell therapy manufacturing site to Cellistic for €6M | N/A | |
| 2022-08-05 13:31 EST | News | Celyad Oncology GAAP EPS of -€0.62 | N/A | |
| 2022-08-05 13:31 EST | News | Celyad Oncology SA's (CYAD) CEO Michel Lussier on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-01 21:07 EST | News | Celyad stock soars 35% as FDA lifts hold on colorectal cancer trial of CYAD-101/Keytruda | N/A | |
| 2022-07-19 12:23 EST | News | Celyad: Probably Still Top-Notch In Oncology | N/A | |
| 2022-03-27 00:44 EST | News | Celyad Oncology SA (CYAD) CEO Filippo Petti on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-03-25 11:24 EST | News | Celyad Oncology GAAP EPS of -€1.70 | N/A | |
| 2022-03-02 12:24 EST | News | Celyad phase 1b colorectal cancer trial put on hold by FDA citing safety after 2 deaths | N/A | |
| 2022-02-28 05:58 EST | News | Celyad pauses phase 1 colorectal cancer trial after reports of two fatalities | N/A | |
| 2022-01-10 14:28 EST | News | Celyad Oncology outlines upcoming milestones for 2022 | N/A | |
| 2021-12-16 21:15 EST | News | Celyad Oncology doses first patient in KEYNOTE-B79 Phase 1b trial | N/A | |
| 2021-12-16 01:11 EST | News | Celyad Oncology (CYAD) Presents 2021 American Society of Hematology Meeting Update - Slideshow | N/A | |
| 2021-12-13 13:58 EST | News | Celyad Oncology presents updates on shRNA-based CAR T programs at ASH meeting | N/A | |
| 2021-12-03 07:47 EST | News | Celyad Oncology raises $32.5M in private placement with Fortress Investment Group | N/A | |
| 2021-11-10 23:36 EST | News | Celyad Oncology reports 9M results | N/A | |
| 2021-08-08 06:59 EST | News | Celyad Oncology SA (CYAD) CEO Filippo Petti on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-08-04 22:11 EST | News | Celyad Oncology EPS beats by $0.29 | N/A | |
| 2021-07-22 17:19 EST | News | Celyad Oncology presents early-stage data from blood cancer trial for CAR-T therapy | N/A | |
| 2021-07-22 17:17 EST | News | Celyad Oncology (CYAD) Presents Corporate Update at EHA 2021 - Slideshow | N/A | |
| 2021-07-22 17:10 EST | News | Celyad Oncology highlights new CAR T product, gives data update | N/A | |
| 2021-05-07 02:12 EST | News | Celyad Oncology reports Q1 results | N/A | |
| 2021-04-19 05:01 EST | News | New medical chief at Celyad Oncology | N/A | |
| 2021-03-26 03:31 EST | News | Celyad Oncology's (CYAD) CEO Filippo Petti on Q4 2020 Results - Earnings Call Transcript | N/A | |
| 2021-03-25 08:01 EST | News | Celyad Oncology reports FY results | N/A | |
| 2021-03-19 01:00 EST | Analyst Rating | The Analyst Target Price has increased from $17.63 to $17.75. | Buy | |
| 2021-03-18 07:49 EST | Analyst Rating | The Analyst Target Price has decreased from $17.66 to $17.63. | Neutral | |
| 2021-03-17 15:43 EST | Analyst Rating | The Analyst Target Price has decreased from $17.7 to $17.66. | Neutral | |
| 2021-03-13 22:28 EST | Analyst Rating | The Analyst Target Price has decreased from $17.74 to $17.7. | Neutral | |
| 2021-03-13 06:14 EST | Analyst Rating | The Analyst Target Price has increased from $17.66 to $17.74. | Buy | |
| 2021-03-12 18:56 EST | News | Celyad Oncology (CYAD) Investor Presentation - Slideshow | N/A | |
| 2021-03-12 14:07 EST | Analyst Rating | The Analyst Target Price has increased from $17.47 to $17.66. | Buy | |
| 2021-03-12 06:36 EST | Analyst Rating | The Analyst Target Price has increased from $17.43 to $17.47. | Buy | |
| 2021-03-11 02:38 EST | Analyst Rating | The Analyst Target Price has increased from $17.36 to $17.43. | Buy | |
| 2021-03-10 06:55 EST | Analyst Rating | The Analyst Target Price has decreased from $17.47 to $17.36. | Neutral | |
| 2021-03-09 02:39 EST | Analyst Rating | The Analyst Target Price has increased from $17.45 to $17.47. | Buy | |
| 2021-03-07 14:21 EST | Analyst Rating | The Analyst Target Price has decreased from $17.53 to $17.45. | Neutral | |
| 2021-03-06 02:32 EST | Analyst Rating | The Analyst Target Price has decreased from $17.65 to $17.53. | Neutral | |
| 2021-03-05 13:58 EST | Analyst Rating | The Analyst Target Price has increased from $17.55 to $17.65. | Buy | |
| 2021-03-04 02:42 EST | Analyst Rating | The Analyst Target Price has increased from $17.49 to $17.55. | Buy | |
| 2021-03-03 03:19 EST | Analyst Rating | The Analyst Target Price has decreased from $17.55 to $17.49. | Neutral | |
| 2021-03-02 02:58 EST | Analyst Rating | The Analyst Target Price has increased from $17.52 to $17.55. | Buy | |
About Celyad Oncology SA (CYAD):
Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company's lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is in preclinical development for the treatment of solid tumors. The company's other preclinical candidates include CYAD-211, a CAR-T candidate targeting B-cell maturation antigen for the treatment of multiple myeloma; CYAD-221, a CAR-T candidate targeting CD19 for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad Oncology has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad Oncology was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
General
- Name Celyad Oncology SA
- Symbol CYAD
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 105
- Fiscal Year EndDecember
- IPO Date2015-06-19
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.celyad.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 8257.94
- Price/Book (Most Recent Quarter) 3.15
- Enterprise Value Revenue 8022.99
View More
Financials
- Most Recent Quarter 2020-06-30
- Return on Assets -22%
- Return on Equity -82%
- Earnings Per Share -$7.01
- Revenue Per Share $0
- Gross Profit 6000
- Quarterly Earnings Growth -99%
View More
Highlights
- Market Capitalization 100.66 million
- Analyst Target Price $17.75
- Book Value Per Share $7.09
View More
Share Statistics
- Shares Outstanding 14.21 million
- Shares Float 9.22 million
- % Held by Insiders <1%
- % Held by Institutions 8.01%
- Shares Short 210938
- Shares Short Prior Month 210951
- Short Ratio 11.55
- Short % of Shares Outstanding 1%
View More
Technicals
- Beta 1.48
- 52 Week High $13.01
- 52 Week Low $5.03
- 50 Day Moving Average 7.78
- 200 Day Moving Average 8.55
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Celyad Oncology SA (CYAD) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Celyad Oncology SA (CYAD) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-03-31 | 2020-06-30 | $N/A | -$0.67 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $6000 | -$0.66 | -$1.30 | 49.55% |
Celyad Oncology SA (CYAD) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Celyad Oncology SA (CYAD) Chart:
Celyad Oncology SA (CYAD) News:
Below you will find a list of latest news for Celyad Oncology SA (CYAD) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Celyad Oncology SA (CYAD) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Latest CYAD Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 6:48 PM EST | 100 | $1.97 |
Celyad Oncology SA (CYAD) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-06-22 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1637890/000119380520000729/0001193805-20-000729-index.htm |
| 2018-09-12 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1637890/000000000018028343/0000000000-18-028343-index.htm |
| 2020-09-04 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1637890/000000000020008358/0000000000-20-008358-index.htm |
| 2019-02-01 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1637890/000104018819000058/0001040188-19-000058-index.htm |
| 2020-01-30 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1637890/000104018820000028/0001040188-20-000028-index.htm |
| 2018-09-05 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518266730/0001193125-18-266730-index.htm |
| 2018-09-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518281669/0001193125-18-281669-index.htm |
| 2018-09-26 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518283407/0001193125-18-283407-index.htm |
| 2018-09-28 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518286506/0001193125-18-286506-index.htm |
| 2018-10-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518292858/0001193125-18-292858-index.htm |
| 2018-10-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518292860/0001193125-18-292860-index.htm |
| 2018-11-01 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518315822/0001193125-18-315822-index.htm |
| 2018-11-13 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518324914/0001193125-18-324914-index.htm |
| 2018-11-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518332098/0001193125-18-332098-index.htm |
| 2018-11-30 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518339018/0001193125-18-339018-index.htm |
| 2018-12-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312518341968/0001193125-18-341968-index.htm |
| 2019-01-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519003079/0001193125-19-003079-index.htm |
| 2019-03-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519069849/0001193125-19-069849-index.htm |
| 2019-03-21 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519081910/0001193125-19-081910-index.htm |
| 2019-04-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519096679/0001193125-19-096679-index.htm |
| 2019-04-05 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519099411/0001193125-19-099411-index.htm |
| 2019-05-15 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519147193/0001193125-19-147193-index.htm |
| 2019-07-03 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519188525/0001193125-19-188525-index.htm |
| 2019-07-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519189986/0001193125-19-189986-index.htm |
| 2019-07-08 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519189991/0001193125-19-189991-index.htm |
| 2019-07-09 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519190864/0001193125-19-190864-index.htm |
| 2019-08-23 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519227354/0001193125-19-227354-index.htm |
| 2019-09-04 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519237039/0001193125-19-237039-index.htm |
| 2019-09-05 | 6-K/A | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519238811/0001193125-19-238811-index.htm |
| 2019-09-10 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519241994/0001193125-19-241994-index.htm |
| 2019-09-12 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519244000/0001193125-19-244000-index.htm |
| 2019-09-12 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519244008/0001193125-19-244008-index.htm |
| 2019-09-16 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519245834/0001193125-19-245834-index.htm |
| 2019-10-02 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312519260272/0001193125-19-260272-index.htm |
| 2020-03-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312520069556/0001193125-20-069556-index.htm |
| 2020-03-25 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312520084239/0001193125-20-084239-index.htm |
| 2020-03-25 | 20-F | Annual and transition report of foreign private issuers [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1637890/000119312520084305/0001193125-20-084305-index.htm |
| 2020-05-06 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312520134578/0001193125-20-134578-index.htm |
| 2020-05-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312520135738/0001193125-20-135738-index.htm |
| 2020-06-10 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312520165154/0001193125-20-165154-index.htm |
| 2020-08-07 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312520212484/0001193125-20-212484-index.htm |
| 2020-08-28 | F-3 | Registration statement by foreign private issuers | https://www.sec.gov/Archives/edgar/data/1637890/000119312520234651/0001193125-20-234651-index.htm |
| 2020-09-03 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1637890/000119312520239029/0001193125-20-239029-index.htm |
| 2020-09-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1637890/000119312520244247/0001193125-20-244247-index.htm |
| 2020-09-11 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312520244253/0001193125-20-244253-index.htm |
| 2020-09-29 | 6-K | Report of foreign issuer [Rules 13a-16 and 15d-16] | https://www.sec.gov/Archives/edgar/data/1637890/000119312520257159/0001193125-20-257159-index.htm |
| 2018-10-15 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1637890/000119380518001228/0001193805-18-001228-index.htm |
| 2020-06-22 | 424B3 | Prospectus [Rule 424(b)(3)] | https://www.sec.gov/Archives/edgar/data/1637890/000119380520000729/0001193805-20-000729-index.htm |
| 2020-09-04 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1637890/999999999520002377/9999999995-20-002377-index.htm |